Cencora beats Q3 expectations, raises full-year earnings outlook

Published 06/08/2025, 11:52
 Cencora beats Q3 expectations, raises full-year earnings outlook

CONSHOHOCKEN, Pa. - On Wednesday, Cencora, Inc. (NYSE:COR) reported third-quarter fiscal 2025 results that exceeded analyst expectations, with adjusted earnings per share of $4.00 beating the consensus estimate of $3.84 and revenue of $80.7 billion surpassing the expected $80.31 billion.

Following the announcement, Cencora shares dipped slightly by 0.46% in pre-market trading.

The pharmaceutical solutions organization saw revenue increase 8.7% YoY, driven by its U.S. Healthcare Solutions segment, which grew 8.5%, and its International Healthcare Solutions segment, which increased 10.5%. Adjusted diluted earnings per share rose 19.8% from $3.34 in the prior year quarter.

"Cencora delivered strong financial results in the third fiscal quarter, driven by our pharmaceutical-centric strategy and focus on our growth priorities," said Robert P. Mauch, President and Chief Executive Officer of Cencora. "Our teams are fueling our growth as they identify opportunities and customer-centric solutions that strengthen our value proposition as the partner of choice."

The company raised its full-year adjusted earnings guidance to a range of $15.85 to $16.00 per share, up from its previous forecast of $15.70 to $15.95 and above the analyst consensus of $15.84. This increase primarily reflects stronger earnings growth in the U.S. Healthcare Solutions segment, where operating income jumped 29.1% in the quarter.

Cencora now expects consolidated revenue growth of approximately 9% for fiscal 2025, with U.S. Healthcare Solutions segment revenue growth of 9-10% and International Healthcare Solutions segment revenue growth of 6-7%.

The company’s Board of Directors declared a quarterly cash dividend of $0.55 per common share, payable September 3, 2025, to stockholders of record at the close of business on August 15, 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.